97 related articles for article (PubMed ID: 21591394)
1. [Drug correction of hormonal disturbances and risk factors of cardiovascular complications in women of reproductive age with polycystic ovary syndrome].
Chernukha GE; Karpov IuA; Balakhonova TV; Blinova IV
Kardiologiia; 2010; 50(12):59-63. PubMed ID: 21591394
[No Abstract] [Full Text] [Related]
2. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
3. Polycystic ovary disease in two patients with Briquet's disorder.
Orenstein H; Raskind MA
Am J Psychiatry; 1983 Sep; 140(9):1202-4. PubMed ID: 6412573
[TBL] [Abstract][Full Text] [Related]
4. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
Ganie MA; Hassan S; Nisar S; Shamas N; Rashid A; Ahmed I; Douhat S; Mudassar S; Jan VM; Rashid F
Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
[TBL] [Abstract][Full Text] [Related]
5. Re: Effects of rosiglitazone on hormonal profile and ovulatory function in Chinese women with polycystic ovary syndrome.
Chan LY; Lau TK; Fung TM; Chow KM
Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):170-1. PubMed ID: 16638044
[No Abstract] [Full Text] [Related]
6. Effect of spironolactone on testosterone and LHRH responsiveness in women with polycystic ovarian disease.
Evron S; Yosef SM; Schenker JG; Diamant YZ
Isr J Med Sci; 1984 Jul; 20(7):630-3. PubMed ID: 6432730
[No Abstract] [Full Text] [Related]
7. The effects of buserelin on the hormonal states in PCOD.
Willemsen WN; Franssen AM; Rolland R; Vemer HM
Prog Clin Biol Res; 1986; 225():377-89. PubMed ID: 3097673
[No Abstract] [Full Text] [Related]
8. [Serum levels of anti-muller hormone in women with polycystic ovary syndrome and healthy women of reproductive age].
Parahuleva N; Pehlivanov B; Orbecova M; Deneva T; Uchikova E
Akush Ginekol (Sofiia); 2013; 52 Suppl 1():16-23. PubMed ID: 24294740
[TBL] [Abstract][Full Text] [Related]
9. [Effect of the antiserotoninergic preparation cyproheptadine on the levels of luteinizing and follicle-stimulating hormones and testosterone in patients with polycystic ovaries].
Tudose TI
Probl Endokrinol (Mosk); 1987; 33(3):22-5. PubMed ID: 3116528
[TBL] [Abstract][Full Text] [Related]
10. Ovarian morphology as a predictor of hormonal values in polycystic ovary syndrome.
van der Westhuizen S; van der Spuy ZM
Ultrasound Obstet Gynecol; 1996 May; 7(5):335-41. PubMed ID: 8774098
[TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone as treatment for clomiphene citrate-resistant polycystic ovary syndrome: factors associated with clinical response.
Shokeir T; El-Kannishy G
J Womens Health (Larchmt); 2008 Nov; 17(9):1445-52. PubMed ID: 18973428
[TBL] [Abstract][Full Text] [Related]
12. [Polycystic ovary syndrome in adolescent gynecology].
Micinski P; Kuczera B; Sirko I; Poreba R
Ginekol Pol; 1999 May; 70(5):370-3. PubMed ID: 10462984
[TBL] [Abstract][Full Text] [Related]
13. Divalent cations in women with PCOS: implications for cardiovascular disease.
Muneyyirci-Delale O; Nacharaju VL; Dalloul M; Jalou S; Rahman M; Altura BM; Altura BT
Gynecol Endocrinol; 2001 Jun; 15(3):198-201. PubMed ID: 11447731
[TBL] [Abstract][Full Text] [Related]
14. Metformin therapy in girls with polycystic ovary syndrome: a self-controlled clinical trial.
Nazari T; Bayat R; Hamedi M
Arch Iran Med; 2007 Apr; 10(2):176-81. PubMed ID: 17367220
[TBL] [Abstract][Full Text] [Related]
15. [Effect of bromocryptin in polycystic ovary syndrome].
Fuhrer J; Cheviakoff S; Rubio V
Rev Chil Obstet Ginecol; 1989; 54(6):364-9; discussion 369-70. PubMed ID: 2485372
[TBL] [Abstract][Full Text] [Related]
16. Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study.
Kazerooni T; Shojaei-Baghini A; Dehbashi S; Asadi N; Ghaffarpasand F; Kazerooni Y
Fertil Steril; 2010 Nov; 94(6):2208-13. PubMed ID: 20079899
[TBL] [Abstract][Full Text] [Related]
17. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of suppression and recovery of plasma FSH, LH, androstenedione and testosterone in polycystic ovarian disease using an oral contraceptive.
Givens JR; Andersen RN; Wiser WL; Fish SA
J Clin Endocrinol Metab; 1974 May; 38(5):727-35. PubMed ID: 4823918
[No Abstract] [Full Text] [Related]
19. [The hormonal profile in the polycystic ovary syndrome].
Donát J; Kohoutek M; Donátová N; Lacinová V
Cesk Gynekol; 1989 Nov; 54(9):684-8. PubMed ID: 2516481
[No Abstract] [Full Text] [Related]
20. Cardiovascular risk in women with polycystic ovary syndrome.
Cho LW; Atkin SL
Minerva Endocrinol; 2007 Dec; 32(4):263-73. PubMed ID: 18091663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
